EX-99.1 2 w99402exv99w1.htm EXHIBIT 99.1 exv99w1
 

(LOGO: The Advisory Board)   Exhibit 99.1
         
Contact:
  David Felsenthal
Chief Financial Officer
202.266.5876
jacobsg@advisory.com
  The Advisory Board Company
2445 M Street, N.W.
Washington, D.C. 20037
www.advisoryboardcompany.com

THE ADVISORY BOARD COMPANY REPORTS
FIRST QUARTER RESULTS FOR FISCAL 2005

Company Reports Quarterly Revenue Growth of 16%; Announces New Research Program;
CEO Frank Williams to Succeed Jeff Zients as Board Chairman

WASHINGTON, D.C. — (July 26, 2004) — The Advisory Board Company (NASDAQ: ABCO) today announced financial results for the first quarter of its fiscal year ending March 31, 2005. For the quarter, revenues increased 16% to $33.0 million, from $28.4 million for the first quarter of fiscal 2004. Net income was $5.6 million, or $0.29 per diluted share, compared to $4.4 million, or $0.24 per diluted share, for the same period a year ago. Pro forma net income for the quarter, which excludes special compensation and stock option related expenses, was also $5.6 million or $0.29 per diluted share, compared to $4.6 million, or $0.25 per diluted share for the same period a year ago. Contract value grew 16% to $130.7 million as of June 30, 2004, up from $113.1 million as of June 30, 2003.

Frank Williams, Chief Executive Officer of The Advisory Board Company, commented, “We are pleased with our financial results for the first quarter as we achieved 16% revenue growth and earnings per diluted share of $0.29, exceeding our targets in a challenging environment. Our network of over 2,300 members and our ability to align our research around our members’ most pressing concerns is the basis for our continued success. The Advisory Board remains the most cost effective alternative for senior healthcare executives seeking proven best practices to address their most important strategic and operational issues.”

Mr. Williams continued, “I am also pleased to announce the launch of our latest research membership initiative, the Human Resources Strategy Program. This new research program offers health care human resources executives the tools to link human resource investments to business strategy in order to enhance organizational performance. Through best practice research, sophisticated survey methodology, and topic-based collaboratives, the program offers an array of tools to facilitate more effective decision-making issues. We have already established a strong charter membership for the program, including the Johns Hopkins Health System, Emory Healthcare, Scripps Healthcare, Seton Healthcare Network in Texas and the University of Wisconsin Hospitals and Clinics. The program is off to a strong start and we are excited about its potential.”

Share Repurchase

During the three months ended June 30, 2004, the Company repurchased 291,166 shares of its common stock at a total cost of approximately $10.0 million.

Outlook for Remainder of Calendar Year 2004

The Company reiterated its previously announced guidance for the next calendar quarter of $34.5 million of revenue and pro forma earnings per diluted share of $0.30. Combined with results from the first half of calendar year 2004, the Company’s full calendar year revenue and pro forma earnings per diluted share guidance is $135.6 million and $1.20 respectively.

 


 

Exhibit 99.1

Board Developments

In other news, the Company announced today that its Board of Directors will be naming Mr. Williams to serve as Chairman of the Board, succeeding Jeffrey D. Zients, effective at the Company’s next annual meeting scheduled for November 15, 2004. Mr. Zients asked that he not be considered for re-nomination to the Board as he will be devoting more time to other responsibilities. Mr. Williams commented, “Jeff Zients has provided strong leadership and guidance to The Advisory Board throughout his tenure with the firm and I want to thank him for his tremendous contributions.” Mr. Williams will remain as the Company’s Chief Executive Officer. Kelt Kindick, one of the Company’s independent directors and Chair of the Board’s Governance Committee, will assume the newly created position of Lead Director in November.

The Company also announced that Michael A. D’Amato also asked that he not be considered for re-nomination to the Board and will be leaving the Board when his term expires. Mr. Williams added, “Mike has provided significant value to the firm over the last several years and we wish him the best in the future.”

The Company will hold an investor conference call to discuss its first quarter performance this evening, July 26, 2004, at 6:00 p.m. Eastern Daylight Time. The conference call will be available via live web cast on the Company’s web site at www.advisoryboardcompany.com in the section entitled “Other Information” found under the tab “About Us.” To participate by telephone, the dial-in number is 800-599-9829 and the access code is 36816103. Investors are advised to log in or dial in at least five minutes prior to the web cast to register. The web cast will be archived on the Company’s web site for seven days, from 8:00 p.m. Monday, July 26th until 8:00 p.m. Monday, August 2nd.

About The Advisory Board Company

The Advisory Board Company provides best practices research and analysis to the health care industry, focusing on business strategy, operations and general management issues. The Company provides best practices and research through discrete annual programs to a membership of over 2,300 hospitals, health systems, pharmaceutical and biotech companies, health care insurers, and medical device companies in the United States. Each program typically charges a fixed annual fee and provides members with best practices, research reports, executive education and other supporting research services.

The Company presents pro forma results to provide comparisons with prior periods in a manner it believes would be consistent if it had been a public company prior to fiscal 2002. Pro forma results exclude special compensation and stock option related expense. A reconciliation between pro forma and GAAP results is shown in the attached schedule. The Company is not able to reconcile its outlook for the remainder of calendar year 2004 to GAAP as stock option related expense is dependent upon a number of unknown factors, including future stock price.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You are hereby cautioned that these statements may be affected by certain factors, among others, set forth below and in the Company’s filings with the Securities and Exchange Commission, and consequently, actual operations and results may differ materially from the results discussed in the forward-looking statements. Factors that could cause actual results to differ materially from those indicated by forward-looking statements include, among others, the dependence on renewal of membership based services, dependence on key personnel, the need to attract and retain qualified personnel, management of growth, new product development, competition, risks associated with anticipating market trends, industry consolidation, variability of quarterly operating results and various factors that could affect the estimated tax rate. These factors are discussed more fully in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.

# # #

 


 

THE ADVISORY BOARD COMPANY
UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS
AND OTHER OPERATING STATISTICS
(In thousands, except per share data)

                         
    Three Months Ending   Selected
Growth
Rates

    June 30,
 
    2004
  2003
 
Statements of Operations
                       
Revenues
  $ 33,025     $ 28,449       16.1 %
 
   
 
     
 
         
Cost of services
    13,674       11,617          
Member relations and marketing
    6,516       5,552          
General and administrative
    3,927       3,692          
Depreciation and loss on disposal of assets
    392       404          
Special compensation and stock option related expense
          321          
 
   
 
     
 
         
Income from operations
    8,516       6,863          
Interest income
    893       581          
 
   
 
     
 
         
Income before provision for income taxes
    9,409       7,444          
Provision for income taxes
    (3,811 )     (3,014 )        
 
   
 
     
 
         
Net income
  $ 5,598     $ 4,430          
 
   
 
     
 
         
Earnings per share
                       
Basic
  $ 0.31     $ 0.29          
Diluted
  $ 0.29     $ 0.24       20.8 %
Weighted average common shares outstanding
                       
Basic
    17,802       15,116          
Diluted
    19,425       18,325          
 
                       
Percentages of Revenues
                       
Cost of services
    41.4 %     40.8 %        
Member relations and marketing
    19.7 %     19.5 %        
General and administrative
    11.9 %     13.0 %        
Depreciation and loss on disposal of assets
    1.2 %     1.4 %        
Income from operations
    25.8 %     24.1 %        
Net income
    17.0 %     15.6 %        
 
                       
Contract Value (at end of period)
  $ 130,710     $ 113,075       15.6 %

RECONCILIATION OF PRO FORMA RESULTS
(In thousands, except per share data)

                         
Pro forma data (1):
                       
Income from operations
  $ 8,516     $ 6,863          
Special compensation and stock option related expense
          321          
 
   
 
     
 
         
Pro forma income from operations
    8,516       7,184          
Interest income
    893       581          
 
   
 
     
 
         
Pro forma income before provision for income taxes
    9,409       7,765          
Pro forma provision for income taxes
    (3,811 )     (3,145 )        
 
   
 
     
 
         
Pro forma net income
  $ 5,598     $ 4,620          
 
   
 
     
 
         
Pro forma earnings per share
                       
Basic
  $ 0.31     $ 0.31          
Diluted
  $ 0.29     $ 0.25       16.0 %
 
                       
Percentages of Revenues
                       
Pro forma income from operations (1)
    25.8 %     25.3 %        
Pro forma net income (1)
    17.0 %     16.2 %        


(1)   Excludes special compensation and stock option related expense.

 


 

THE ADVISORY BOARD COMPANY
CONSOLIDATED BALANCE SHEETS
(In thousands)

                 
    June 30,   March 31,
    2004
  2004
    (unaudited)        
ASSETS
               
Current assets:
               
Cash and cash equivalents
  $ 23,095     $ 41,389  
Marketable securities
          3,737  
Membership fees receivable, net
    20,513       14,338  
Prepaid expenses and other current assets
    3,341       3,121  
Deferred income taxes
    17,312       17,123  
Deferred incentive compensation
    2,602       2,375  
 
   
 
     
 
 
Total current assets
    66,863       82,083  
Fixed assets, net
    9,797       6,701  
Deferred income taxes, net of current portion
    17,955       20,532  
Marketable securities
    101,670       94,683  
 
   
 
     
 
 
Total assets
  $ 196,285     $ 203,999  
 
   
 
     
 
 
 
               
LIABILITIES AND STOCKHOLDERS’ EQUITY
               
Current liabilities:
               
Deferred revenues
  $ 71,555     $ 72,410  
Accounts payable and accrued liabilities
    8,292       8,262  
Accrued incentive compensation
    5,677       7,704  
 
   
 
     
 
 
Total current liabilities
    85,524       88,376  
Long-term liabilities:
               
Other liabilities
    1,390        
 
   
 
     
 
 
Total liabilities
    86,914       88,376  
 
   
 
     
 
 
 
               
Stockholders’ equity:
               
Common stock
    183       183  
Additional paid-in capital
    88,986       88,885  
Retained earnings
    43,292       37,694  
Accumulated elements of comprehensive income
    (952 )     1,031  
Treasury stock
    (22,138 )     (12,170 )
 
   
 
     
 
 
Total stockholders’ equity
    109,371       115,623  
 
   
 
     
 
 
Total liabilities and stockholders’ equity
  $ 196,285     $ 203,999  
 
   
 
     
 
 

 


 

THE ADVISORY BOARD COMPANY
UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)

                 
    Three Months Ended June 30,
    2004
  2003
Cash flows from operating activities:
               
Net income
  $ 5,598     $ 4,430  
Adjustments to reconcile net income to net cash provided by operating activities -
               
Depreciation
    392       404  
Deferred income taxes
    3,736       3,003  
Amortization of marketable securities premiums
    209       185  
Changes in operating assets and liabilities:
               
Member fees receivable
    (6,175 )     (3,136 )
Prepaid expenses and other current assets
    (220 )     324  
Deferred incentive compensation
    (227 )     (27 )
Deferred revenues
    (855 )     (143 )
Accounts payable and accrued liabilities
    30       522  
Accrued incentive compensation
    (2,027 )     (2,110 )
Other liabilities
    1,390        
 
   
 
     
 
 
Net cash flows provided by operating activities
    1,851       3,452  
 
   
 
     
 
 
 
               
Cash flows from investing activities:
               
Purchases of property and equipment
    (3,488 )     (137 )
Redemption of marketable securities
    5,713       6,000  
Purchase of marketable securities
    (12,500 )     (11,059 )
 
   
 
     
 
 
Net cash flows used in investing activities
    (10,275 )     (5,196 )
 
   
 
     
 
 
 
               
Cash flows from financing activities:
               
Proceeds on issuance of stock from exercise of stock options
    17       3,515  
Purchases of treasury stock
    (9,968 )      
Proceeds on issuance of stock under ESPP
    81       79  
 
   
 
     
 
 
Net cash flows (used in) provided by financing activities
    (9,870 )     3,594  
 
   
 
     
 
 
 
               
Net (decrease) increase in cash and cash equivalents
    (18,294 )     1,850  
Cash and cash equivalents, beginning of period
    41,389       33,301  
 
   
 
     
 
 
Cash and cash equivalents, end of period
  $ 23,095     $ 35,151